ADVERSE EVENT REPORTING OF MARKETING BIOSIMILAR AND BIOLOGICAL MONOCLONAL ANTIBODY CANCER TREATMENTS

被引：0
|
作者：
Xue, X. Xiangzhong [1 ]
Qian, J. [1 ]
机构：
[1] Auburn Univ, Harrison Coll Pharm, Auburn, AL USA
来源：
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY | 2023年 / 19卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：564 / 564
页数：1
相关论文
共 50 条
  • [41] Exploring Adverse Event Reporting Patterns of Newly Approved Anti-Cancer Drugs in the Japanese Adverse Drug Event Report (JADER) Database
    Matsuda, Shinichi
    Hamada, Kenji
    Aoki, Kotonari
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 282 - 283
  • [42] Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system
    Li, Huqun
    Wang, Chongshu
    Guo, Cuilian
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [43] Safety of remdesivir in COVID-19 patients: post-marketing evaluation on spontaneous adverse event reporting system
    Cesaro, M.
    Rafaniello, C.
    Di Mauro, C.
    Zinzi, A.
    Ferrajolo, C.
    Scavone, C.
    Sportiello, L.
    Sullo, M.
    Rossi, F.
    Capuano, A.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S116 - S117
  • [44] Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
    Liu, Yan-xin
    Dong, Chang-jiang
    He, Xu-cheng
    Shu, Ya-min
    Wu, Pan
    Zou, Jian
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2022, 25 : 377 - 390
  • [45] Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS)
    Wittayanukorn, Saranrat
    Qian, Jingjing
    Johnson, Brandon S.
    Hansen, Richard A.
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (02) : 93 - 102
  • [46] A systematic review of adverse event reporting in companion animal clinical trials evaluating cancer treatment
    Giuffrida, Michelle A.
    [J]. JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2016, 249 (09): : 1079 - 1087
  • [47] Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)
    Mao, KaiLi
    Chen, Ping
    Sun, HuaYu
    Zhong, SongYang
    Zheng, HongLiang
    Xu, LuYao
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [48] Antiviral influenza treatments and hemorrhage-related adverse events in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database
    Sarker, Jyotirmoy
    Carkovic, Emir
    Ptaszek, Karolina
    Lee, Todd A.
    [J]. PHARMACOTHERAPY, 2024, 44 (05): : 383 - 393
  • [49] Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system
    Zhu, Zhou
    Liu, Mingjuan
    Zhang, Hanlin
    Zheng, Heyi
    Li, Jun
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [50] Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
    Gastaldon, Chiara
    Raschi, Emanuel
    Kane, John M.
    Barbui, Corrado
    Schoretsanitis, Georgios
    [J]. PSYCHOTHERAPY AND PSYCHOSOMATICS, 2020, 90 (01) : 41 - 48
12345